Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine
the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or
overweight subjects.